Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors

Haematologica

Volumn 95, Issue 12, 2010, Pages 2119-2125

  Gupta, Vikas ^a   Eapen, Mary ^b   Brazauskas, Ruta ^b   Carreras, Jeanette ^b   Aljurf, Mahmoud ^c   Gale, Robert Peter ^d   Hale, Gregory A ^e   Ilhan, Osman ^f   Passweg, Jakob R ^g   Ringdén, Ollé ^h   Sabloff, Mitchell ⁱ   Schrezenmeier, Hubert ^j   Socié, Gerard ^k   Marsh, Judith C W ^l  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d CELGENE CORPORATION   (United States)

^e JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^f ANKARA UNIVERSITY   (Turkey)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j University of Ulm   (Germany)

^k SAINT LOUIS HOSPITAL   (France)

^l KING S COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

HLA identical sibling donor; Overall survival; Patient age; Severe aplastic anemia; Transplantation

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; FLUDARABINE; METHOTREXATE; THYMOCYTE ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEUTROPHIL; OVERALL SURVIVAL; PERFORMANCE MEASUREMENT SYSTEM; RISK FACTOR; SCORING SYSTEM; SIBLING; SURVIVAL RATE;

ADULT; AGE FACTORS; ANEMIA, APLASTIC; BLOOD DONORS; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SIBLINGS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649932299     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.026682     Document Type: Article

References (26)

1. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70.
2. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-19.
3. Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med. 1997; 126(2):107-15.
4. Gupta V, Marsh J. Acquired aplastic anemia and Fanconi anemia. In: Barrett J, Trealeaven J, editors. Practical Stem Cell Transplantation. 2009;165-77.
5. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144(2):206-16.
6. Bacigalupo A. Treatment strategies for patients with severe aplastic anemia. Bone Marrow Transplant. 2008;42 (Suppl 1):S42-4.
7. Bagby GC, Lipton JM, Sloand EM, Schiffer CA. Marrow failure. Hematology Am Soc Hematol Educ Program. 2004:318-36.
8. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy - the European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37(1):69-80.
9. Bacigalupo A, Oneto R, Bruno B, Socie G, Passweg J, Locasciulli A, et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol. 2000;103(1):19-25.
10. Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103(7): 2490-7.
11. Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11-8.
12. Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socie G, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabinebased conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94(9):1312-5.
13. Siegal D, Xu W, Sutherland R, Kamel-Reid S, Kuruvilla J, Lipton JH, et al. Graft-versushost disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplant. 2008;42(1):51-6.
14. Gupta V, Ball SE, Yi QL, Sage D, McCann SR, Lawler M, et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti- CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant. 2004;10(12): 867-76.
15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-8.
16. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graftversus- host disease. Hematol Oncol Clin North Am. 1999;13(5):1091-112, viii-ix.
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;30;18(6):695-706.
18. Klein J, Moeschberger M. Survival Analysis: Techniques of Censored and truncated Data. 2nd ed. New York: Springer-Verlag; 2003.
19. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003; 289(9):1130-5.
20. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow- up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101(4):1236-42.
21. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 1993; 329(16):1152-7.
22. Gupta V, Ball SE, Sage D, Ortin M, Freires M, Gordon-Smith EC, et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant. 2005;35(5):467-71.
23. George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant. 2007;40(1):13-8.
24. Dulley FL, Vigorito AC, Aranha FJ, Sturaro D, Ruiz MA, Saboya R, et al. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant. 2004;33(1):9-13.
25. Resnick IB, Aker M, Shapira MY, Tsirigotis PD, Bitan M, Abdul-Hai A, et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine- based preparative regimen. Br J Haematol. 2006;133(6):649-54.
26. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341(1):14-21.